On Monday we gained from Sir Patrick Vallance, the federal government’s Chief Scientific Consultant that Coronavirus will probably never ever vanish and a vaccine will not stop it totally. He also stated that ministers and specialists must stop ‘over-promising’ and be practical about the prospects of a vaccine and the most likely timeline of one, not likely prior to spring next year.
He then echoed his earlier cautions and those of his colleague Professor Chris Whitty that the COVID-19 fight will be a long one, and it will be with us for great.
So, from this should we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there were a single treatment that:
- could stop the infection in its tracks,
- was anti-inflammatory; controlling the immune system’s action to the infection and stopping it from overreacting dangerously,
- in cases where clients established secondary bacterial infections in the lungs could supercharge antibiotics; improving their effectiveness and eve,
- was a repurposed drug; already proven as safe
- was simple to make, scalable at the level required to make a difference in the pandemic and was cost efficient, then wouldn’t that be something we should all be tingling about?
Certainly though no such ‘silver bullet’ video game changing treatment exists? The only treatments we hear about for COVID are those which President Trump took, which were either very brand-new, costly and speculative or have a really narrow application to a particular aspect of the illness.
Well, you heard it here first – such a ‘silver bullet’ treatment does exist today. It’s called Nylexa ®, from the little UK biotech company NovaBiotics Ltd. It’s active components have been safely used in medicines that treat unassociated conditions for over 30 years.
NovaBiotics discovered Nylexa’s prospective benefits in COVID-19 following a years of research in hard to treat, drug-resistant infections, including the complex chest infections and inflammation connected with cystic fibrosis (CF) lung illness. In March they looked for a ₤ 1m grant from Innovate UK (representing the government) to start clinical studies. That grant was ultimately granted previously this month, and the government are now considering whether or not to consist of Nylexa on two separate NHS platform research studies.
However why, I hear you ask, if this is so excellent have we not found out about it before? Why are the federal government and journalism not shouting about this from the rooftops? Why is this not being demanded by clinicians desperate for reliable treatments for their clients?
I’m afraid to state, everything boils down to cash. Small biotech business find it hard to get attention as they do not have the resources offered to their larger better financed competitors. The names we read about routinely when it concerns ground breaking new treatments are inevitably big multi-national pharmaceutical companies with deep pockets and huge spending plans to promote their own particular products. They make sure their drugs get the necessary attention. NovaBiotics is a little personal business moneyed by a group of faithful and encouraging investors so unfortunately don’t have the resources to contend for attention with the big young boys.
Which is why this circumstance is so frustrating. In alleviating the health repercussions of contracting COVID-19, Nylexa ® could increase public confidence of dealing with the virus for the longer term and possibly enable a greater degree of normality to go back to the way in which we live, benefiting the economy directly in addition to alleviating COVID-19’s burden on the NHS and healthcare systems internationally. Getting individuals in positions of impact to take notice among all the others contending for their attention is very difficult.
It is reported that there are countless possible COVID-19 treatments in scientific trials throughout the world. I would challenge anybody to reveal me one which has the exact same potential for favorable impact as Nylexa ®, yet this is not presently part of any trial, in spite of its flawless qualifications. So begun UK Federal government, and ministers, get your finger out and get this drug into trials right away. The quicker it gets evaluated, the quicker it can be utilized to help sort out the mess the pandemic has triggered to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology business concentrated on the design and advancement of first-in-class therapies for difficult-to-treat, clinically unmet infectious diseases brought on by bacteria and fungis and respiratory conditions including cystic fibrosis and COVID-19
A leading innovator in the anti-infectives area, the Company’s robust innovation and business model has been validated through successful development, from principle to late phase clinical advancement, of its most sophisticated product candidates. In addition to the lead Nylexa ® programme and the Company’s other late-stage properties (Lynovex ® for cystic fibrosis, NP213/ Novexatin ® for onychomycosis), NovaBiotics has actually created a robust pipeline of earlier phase, high-value drug prospects including NP339(Department of Health and Social Care funded program) for life threatening, drug resistant invasive fungal illness and NP432 for multi- drug resistant bacterial infections.
About Nylexa ®
Nylexa ® is an unique, dual antimicrobial-immunomodulatory candidate treatment. It is an easy, small molecule which has broad varying antimicrobial effects through directly targeting microbes and likewise modulating the body’s ability to control infection. Importantly, Nylexa’s active ingredient has a crucial role in the resolution of infection and control of swelling which NovaBiotics has exploited as a service to COVID-19
For bacterial infections, Nylexa is a potential service to a public health obstacle even greater than COVID-19: the aggravating antimicrobial biotic resistance (AMR) crisis. Because Nylexa’s active ingredient is repurposed and has actually been utilized in medications for other, unrelated conditions for more than 30 years, it can possibly be presented into medical practice within a much shorter timescale than brand-new antibiotic( s) treatments developed from first principle. In other words, Nylexa ® ‘turbo charges’ existing prescription antibiotics in bacterial infections, specifically against drug resistant bacteria.
For additional info contact
Dr Deborah O’Neil – CEO & & CSO